N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study
N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study
复制标题
DOI：
10.1080/23744235.2021.1945675
复制
发表时间：
2021-06-26
影响因子：
5.8
通讯作者：
Marangos, Markos
中科院分区：
文献类型：
--
作者：
Assimakopoulos, Stelios F.;Aretha, Diamanto;Marangos, Markos
背景N-乙酰半胱氨酸（NAC）在多种呼吸系统疾病中通过抗氧化和抗炎作用发挥有益作用。我们的目的是评估NAC对住院的COVID-19肺炎患者在进展为严重呼吸衰竭（SRF）和死亡率方面的潜在影响。患者和方法这项回顾性、双中心队列研究纳入了因中度或重度COVID-19肺炎住院的连续患者。将接受标准治疗的患者与另外接受NAC 600 mg bid口服14天的患者进行比较。记录患者的临床过程，包括（i）SRF的发展（PO 2/FiO（2））
Background N-acetyl-cysteine (NAC) has been previously shown to exert beneficial effects in diverse respiratory diseases, through antioxidant and anti-inflammatory actions. Our aim was to evaluate NAC potential impact in hospitalised patients with COVID-19 pneumonia, in terms of progression to severe respiratory failure (SRF) and mortality. Patients and Methods This retrospective, two-centre cohort study included consecutive patients hospitalised with moderate or severe COVID-19 pneumonia. Patients who received standard of care were compared with patients who additionally received NAC 600 mg bid orally for 14 days. Patients' clinical course was recorded regarding (i) the development of SRF (PO2/FiO(2)